nDatalyze Corp.

NEWS RELEASE

nDatalyze announces its upcoming interactive presentation at VirtualInvestorConferences.com

Calgary, Alberta – February 22, 2022

For Immediate Release – nDatalyze Corp. ("**NDAT**" or the "**Corporation**") (CSE:NDAT, OTCQB:NDATF) is pleased to announce the Corporation's participation in a live, interactive investor presentation conducted by VirtualInvestorConferences.com.

Jim Durward, CEO, commented, "Now that we have upgraded our US listing to the OTCQB to increase access to our shares by American investors, we are acting to increase the Corporation's market visibility with a goal of enhancing our trading liquidity."

The presentation will be a live, interactive online event where investors are invited to ask the company questions in real-time. Topics of discussion will include the mHealth market, Proprietary Database, the recently-completed marketing study and how it has influenced system development, and the current system state and expected roll-out timetable. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event. It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates.

Learn more about the event at www.virtualinvestorconferences.com.

The Corporation further reports that it has closed the first tranche of $250,000 of its current financing.

About nDatalyze Corp.:

nDatalyze Corp. generates technology-based, health-related solutions. The YMI division is developing a machine-learning based, online consumer mental health application and the MLdelic division is focusing on applying machine-learning to assist in the prediction of potential benefits associated with the use of entheogenic compounds within the mental health sector. Both YMI and MLdelic are based on the Corporation's proprietary Reference Database consisting of >1200 biometric records complete with "same-time-of-day" EEG data. With installations worldwide, its Medxtractor division manufactures and sells small-scale bio-extractors that are used to extract compounds from a variety of botanical biomasses. While the Medxtractor division is currently generating cash flow, both YMI and MLdelic are in development and accordingly the Corporation cannot accurately predict if or when these applications will become cash flow generators.

FOR FURTHER INFORMATION, PLEASE CONTACT:

nDatalyze Corp.
James Durward, President and CEO
Telephone: (403) 689-3901
Email: jimd@ndatalyze.com   Website: www.ndatalyze.com

The information in this news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute forward looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward looking statements. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Corporation believes that the expectations reflected in forward looking statements are reasonable, it can give no assurances that the expectations of any forward-looking statements will prove to be correct. Except as required by law, the Corporation disclaims any intention and assumes no obligation to update or revise any forward looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward looking statements or otherwise.